Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually in the following conference in January 2022:
H.C. Wainwright BioConnect 2022 Conference
Dates: Monday, January 10 to Thursday, January 13, 2022
Presentation: On-demand starting January 10, 7 a.m. ET / 1 p.m. CET
Presenter: Filippo Petti, CEO